Intracerebral haemorrhage - mechanisms, diagnosis and prospects for treatment and prevention
- PMID: 39548285
- DOI: 10.1038/s41582-024-01035-w
Intracerebral haemorrhage - mechanisms, diagnosis and prospects for treatment and prevention
Abstract
Intracerebral haemorrhage (ICH) is a devastating condition associated with high mortality and substantial residual disability among survivors. Effective treatments for the acute stages of ICH are limited. However, promising findings from randomized trials of therapeutic strategies, including acute care bundles that target anticoagulation therapies, blood pressure control and other physiological parameters, and trials of minimally invasive neurosurgical procedures have led to renewed optimism that patient outcomes can be improved. Currently ongoing areas of research for acute treatment include anti-inflammatory and haemostatic treatments. The implementation of effective secondary prevention strategies requires an understanding of the aetiology of ICH, which involves vascular and brain parenchymal imaging; the use of neuroimaging markers of cerebral small vessel disease improves classification with prognostic relevance. Other data underline the importance of preventing not only recurrent ICH but also ischaemic stroke and cardiovascular events in survivors of ICH. Ongoing and planned randomized controlled trials will assess the efficacy of prevention strategies, including antiplatelet agents, oral anticoagulants or left atrial appendage occlusion (in patients with concomitant atrial fibrillation), and optimal management of long-term blood pressure and statin use. Together, these advances herald a new era of improved understanding and effective interventions to reduce the burden of ICH.
© 2024. Springer Nature Limited.
Conflict of interest statement
Competing interests: DJW reports speaking honoraria from Bayer; speaking and chairing honoraria from Alexion and NovoNordisk; and consultancy fees from Alnylam, Bayer and NovoNordisk. He is Co-Chief Investigator for the PROHIBIT-ICH trial. He has participated as a member of the LACI-2, TICH-2, TICH-3, RESTART, MACE-ICH and PLINTH Trial Steering Committees. The other authors declare no competing interests.
References
-
- GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 20, 795–820 (2021). - DOI
-
- Foster, L. et al. Effect of deferoxamine on trajectory of recovery after intracerebral hemorrhage: a post hoc analysis of the i-DEF trial. Stroke https://doi.org/10.1161/strokeaha.121.037298 (2022).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources